AstraZeneca struck a wide-ranging collaboration with China’s CSPC Pharmaceutical Group to acquire development and commercialization rights across an eight‑program obesity and diabetes portfolio. The deal includes $1.2 billion upfront, R&D milestones and up to $18.5 billion in potential payments, and centers on CSPC’s long‑acting peptide SYH2082 and related GLP‑1/GIP candidates. AstraZeneca said it will advance those assets globally while CSPC retains select Greater China rights and manufacturing know‑how. The agreement signals a major multinational push to secure next‑generation peptide obesity franchises and expand one‑month dosing options in a crowded GLP‑1 era.